ImmunityBio (IBRX) Change in Cash (2014 - 2026)

ImmunityBio (IBRX) has reported Change in Cash for 13 consecutive years, with $117.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 241.41% year-over-year to $117.0 million; the TTM figure through Mar 2026 stood at $145.3 million (up 301.21% YoY), while the FY2025 annual figure was -$54.5 million, up 55.3% from the prior year.
• Change in Cash advanced to $117.0 million in Q1 2026 per IBRX's latest filing, from $28.1 million in the prior quarter.
• Across five years, Change in Cash topped out at $134.5 million in Q3 2023 and bottomed at -$144.7 million in Q1 2022.
• Historically, Change in Cash has averaged $1.5 million across 5 years, with a median of $480000.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Cash tumbled 1582.14% — and 2023, when it soared 18127.08%.
• ImmunityBio's Change in Cash stood at $480000.0 in 2022, then jumped by 18127.08% to $87.5 million in 2023, then slumped by 63.87% to $31.6 million in 2024, then fell by 11.13% to $28.1 million in 2025, then soared by 316.6% to $117.0 million in 2026.
• Business Quant data shows IBRX's Change in Cash at $117.0 million in Q1 2026, $28.1 million in Q4 2025, and -$76.8 million in Q3 2025.